CA3159265C — Crystalline form of acetylcholinesterase inhibitor and preparation method therefor and application thereof
Assigned to Jiangsu Kanion Pharmaceutical Co Ltd · Expires 2024-06-04 · 2y expired
What this patent protects
The present invention provides a crystalline foun of an acetylcholinesterase inhibitor, a preparation method therefor and application thereof. Specifically, the crystalline form is crystalline form A, crystalline form B and crystalline form C of 24(1-(2-fluorobenzy1)-4-fluoropip…
USPTO Abstract
The present invention provides a crystalline foun of an acetylcholinesterase inhibitor, a preparation method therefor and application thereof. Specifically, the crystalline form is crystalline form A, crystalline form B and crystalline form C of 24(1-(2-fluorobenzy1)-4-fluoropiperidin-4-y1) methylene)-5, 6-dimethoxy-2, 3-dihydro-1-indanone. The crystalline form of the present invention does not contain water and solvent, has high stability and low hygroscopicity, is easy to process, and is very suitable for preparing drugs for preventing and/or treating neurodegenerative diseases.
Drugs covered by this patent
- Ohtuvayre (ENSIFENTRINE) · Verona Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.